Violeta Jardin: Measuring Antifibrinolytic Effect to Improve Tranexamic Acid Safety
Violeta Jardin, General Manager at Haemoview Diagnostics, shared a post on LinkedIn about a recent article by Kaiki Oya et al, published in A and A Practice, adding:
“Tranexamic acid (TXA) is central to bleeding control in cardiac surgery, yet high cumulative dosing around cardiopulmonary bypass is linked to perioperative seizures and prolonged antifibrinolytic shutdown, particularly in patients with renal impairment.
This new case report of TXA-induced seizure immediately after CPB highlights the need for individualized TXA strategies and real-time assessment of its neuro- and haemostatic impact.
The ClotPro TPA-test offers the only viscoelastic quantification of TXA-induced inhibition of tPA-triggered fibrinolysis, allowing titration to effect rather than fixed dosing and supporting safer, lower-dose TXA regimens in high‑risk patients.
Yoshii et al. show that even a 1 g TXA bolus produces measurable, sustained antifibrinolytic activity, with TPA-test parameters closely tracking impaired eGFR—providing a practical tool to avoid TXA overdosing and balance bleeding, seizure, and thrombotic risk post‑cardiac surgery.”
Title: Tranexamic Acid-Induced Seizure After Cardiopulmonary Bypass: A Case Report
Authors: Kaiki Oya, Jun Maki, Midoriko Higashi
Read the Full Article on British Journal of Anaesthesia.
Title: Point-of-care testing for tranexamic acid efficacy: a proof-of-concept study in cardiac surgical patients
Authors: Ryogo Yoshii, Yuya Takahashi, Kenichi A. Tanaka, Hidetake Kawajiri, Teiji Sawa, Fumimasa Amaya, Satoru Ogawa
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 29, 2026, 14:59Global Von Willebrand Disease Diversity Webinar Now Available on EHC YouTube – EHC
-
Sep 29, 2026, 14:43Mary Cushman: Apply to Shape Scientific Publishing as ISTH Associate Editor
-
Sep 29, 2026, 14:32Honoring Women Leaders Advancing Research, Care, and Innovation in Thrombosis and Hemostasis – Seminars in Thrombosis and Hemostasis
-
Sep 29, 2026, 14:20Nathan Connell: Key Takeaways from the 8th Aland Island Meeting on von Willebrand Disease
-
Sep 29, 2026, 14:09Mariusz Ratajczak: Are We Inadvertently Destroying the True Regenerative Power of PRP by Discarding the Plasma?
-
Sep 29, 2026, 14:00Nithin M: Proximal Splenic Artery Embolization Prior to Shunt-Directed Variceal Therapy
-
Sep 29, 2026, 13:12Wolfgang Miesbach: Teclistamab Targets the Source of Pathogenic Autoantibodies
-
Sep 29, 2026, 12:37Dan Milikovsky: Uncovering Cerebrovascular Injury in Sickle Cell Disease
-
Sep 29, 2026, 12:02Hajra Malik: Bridging Language Gaps in Hematology With AI